Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Status: Completed

Conditions: Wiskott-Aldrich Syndrome

Treatments: Drug: Romiplostim

Study type: Observational

Funder types: Other

Identifiers

NCT04350164

NCPHOI-2020-02

Details and patient eligibility

About

The rationale for this retrospective study is to evaluate the efficacy and safety of thrombopoietin-receptor agonist (TPO-RA) romiplostim for reducing thrombocytopenia and bleeding tendency in pediatric participants with genetically confirmed Wiskott-Aldrich syndrome (WAS).

Full description

Thrombocytopenia is a life-threatening symptom in WAS patients. Subjects with WAS are at increased risk of debilitating and\ or life-threatening bleedings due to low platelet numbers. Hematopoietic stem cell transplantation is an effective treatment of WAS and all its symptoms yet requires time for donor search and is not widely utilized in cases with mild WAS with isolated thrombocytopenia. TPO-RAs have been used in individual WAS patients, wherein publications describing large WAS cohorts treated with TPO-RAs are lacking.

Based on the previous reports, WAS patients in our Center have been receiving treatment with TPO-RA romiplostim since 2012.

The aim of the study is to retrospective analyze patients' data in order to asses treatment efficacy and safety of romiplostim in WAS thrombocytopenia.

The study will collect and analyze information that is already in the patients' medical records. Information about clinical data (assessment of bleeding tendency with a modified World Health Organization (WHO) Bleeding Scale), laboratory values (such as clinical and biochemical analysis of blood) will be included.

Evaluation of the efficacy therapy was based on the results of physical examination, including bleeding events at the time of diagnosis and after 6-month TPO-RA was initiated and platelet response. A complete response was defined as a platelet count >100 x 109/L in the absence of bleeding symptoms, partial - 30 x 109/L higher than the patient's pretreatment baseline count to 100 x 109/L. Non-response was defined as not achieving a platelet count of > 30 x 109/L from the baseline count.

Enrollment: 67 patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age under < 18 years
• Subject/legal representative has signed written informed consent. ?
• Subjects diagnosed with WAS based on genetic findings.
• Subjects with thrombocytopenia (platelet count of less than 70 x 109/L).
• Subjects with a history of bleeding.
• Subjects received treatment with romiplostim 8-9 µg /kg for at least 30 days
• Available records of the points of analysis

Exclusion criteria

• Patients, who do not meet the inclusion criteria.

Trial design

67 participants in 1 patient group

treatment

Description:

romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.

Treatment:

Drug: Romiplostim